D086 + D337

D086 + D337 refers to the co-administration of two investigational drugs, **D086** and **D337**, which have been studied in clinical trials primarily in South Korea for potential use in cardiovascular conditions such as **hypertension** and **hyperlipidemia**[3][6]. The individual mechanisms of action for both D086 and D337 have not been publicly defined. D086 is described as a new molecular entity classified as both an antihyperlipidemic and antihypertensive agent, with Chong Kun Dang as the originator[6]. The combination has been used as a reference drug comparator in clinical trials against CKD-391, a fixed-dose combination intended for similar indications[3].